Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
FDA approves Dupixent for adults with poorly controlled COPD
FDA approves Dupixent as add-on treatment for poorly controlled COPD in adults with high eosinophil counts, marking the first biologic therapy for COPD in the U.S. Dupixent, developed by Sanofi and Regeneron, targets type 2 inflammation, reducing flare-ups and improving lung function and quality of life. The approval is based on Phase 3 trials BOREAS and NOTUS, showing significant reductions in exacerbations and improvements in lung health.
Related Clinical Trials:
Regeneron, Sanofi's Dupixent approved for COPD in US, China
Regeneron and Sanofi's Dupixent (dupilumab) approved in US and China for COPD treatment, targeting interleukin 4 and 13. FDA and NMPA approvals based on Phase 3 trials showing reduced exacerbations and improved quality of life.
Dupixent approved in China as the first-ever biologic medicine for patients
Dupixent (dupilumab) approved in China for uncontrolled COPD with raised blood eosinophils, offering new hope for patients on triple therapy.
Dupixent approved in the US as the first-ever biologic medicine for patients ...
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, offering potential for improved breathing and fewer exacerbations.
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Innate Pharma SA will co-host a hybrid scientific symposium on October 3, 2024, with Mount Sinai, featuring key opinion leaders in immunotherapy. The event marks Innate Pharma's 25th anniversary and highlights next-generation immunotherapy discoveries.
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
Dupixent, a drug by Sanofi and Regeneron, has received FDA approval for treating COPD, becoming the first biologic therapy for the condition. The drug targets type 2 inflammation driven by eosinophils, showing significant reductions in COPD exacerbations in Phase 3 trials. Dupixent has previously been approved for dermatitis and asthma, contributing to €10.7 billion in sales in 2023.
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Nemolizumab therapy showed continuous improvements in atopic dermatitis symptoms up to 56 weeks, with 47% achieving clear or almost clear skin and 73% improving EASI scores by 75%. Nemolizumab, an IL-31 receptor antagonist, demonstrated a favorable safety profile with no unexpected adverse events, positioning it as a valuable long-term treatment option for atopic dermatitis.
Sanofi, Regeneron get USFDA nod for Dupixent for COPD
The FDA approved Sanofi's Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype, marking the first biologic medicine for these patients. Dupixent demonstrated a 30-34% reduction in annualized moderate or severe COPD exacerbations, improved lung function, and enhanced quality of life in phase 3 studies.
FDA Approves Dupixent for Patients with COPD
FDA approves Dupixent as add-on treatment for adults with uncontrolled COPD, marking the first biologic therapy for this condition. Dupixent, developed by Sanofi and Regeneron, targets type 2 inflammation pathways and has shown efficacy in reducing COPD exacerbations and improving lung function in phase 3 trials. The drug also has other approved uses and is being studied for bullous pemphigoid.
Dupixent approved in the US as the first-ever biologic medicine for patients
Dupixent approved by FDA as the first biologic medicine for adults with inadequately controlled COPD and an eosinophilic phenotype, based on phase 3 studies showing significant reduction in exacerbations, improvements in lung function, and health-related quality of life.
© Copyright 2025. All Rights Reserved by MedPath